Nano Mask, Inc. announces that it has launched a complete line of Nano Silver Technology Hospital Curtains which is being manufactured by an ISO 2010 certified manufacturer. The complete line is now available for sale in the United States and Europe.
Nano Silver Technology is an antimicrobial colloid composed of silver nanoparticles stabilized by polymer that exhibits excellent antimicrobial efficacy across a wide spectrum of microorganisms. Silver has long been known to inhibit the oxygen exchange in bacteria, killing the bacteria. Nano Silver Technology has been demonstrated to prolong and enhance that effect. Its super-charged magnetic attraction pulls the abnormal DNA of viruses, so it cannot reproduce, thus killing viruses.
In testing, Nano Silver Technology testing has demonstrated the ability to eradicate Staphylococcus aureus, ATCC 6538P and Klebsiella pneumonia and ATCC 4352. In addition, the Nano Silver Curtains are flame-proof (Type C), anti-static, dust-proof; disposable; recyclable, and mildew-proof and are available in three different styles and 13 different colors.
Â
Nano Mask believes that the introduction of this advanced anti-bacterial technology may reduce the risk to patients, staff and visitors of hospital-acquired infections by eliminating certain pathogens, molds and fungi that come into contact with the curtain. In most cases Nano Mask believes its Nano Silver Technology Curtains offer a considerable cost saving when compared to conventional systems and will not only help to saves lives and reduce clinical costs (including infection treatment costs), but will also reduce capital, labor and laundry costs. Nano Mask plans to launch this product in the United States and international markets immediately through its network of distributors and manufacturers' representatives servicing the hospital market.
For more information, visit www.nanoprotectionsolutions.com
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.